期刊文献+

2-羟丙基-β-环糊精对氯诺昔康的增溶作用 被引量:9

The Solubilization Effect of 2-hydroxypropy1-β-cyclodextrin on Lornoxicam
下载PDF
导出
摘要 目的考察不同pH条件下不同浓度的2-羟丙基-β-环糊精溶液对氯诺昔康的增溶作用。方法在室温下运用相溶解度法对氯诺昔康的溶解性进行实验,采用紫外分光光度法测定氯诺昔康在溶液中的浓度。包合物的表观稳定常数由回归方程求得:K=斜率/截距(1-斜率)。结果随着2-羟丙基-β-环糊精浓度的增加和pH的增大,氯诺昔康的溶解度显著提高,在pH7、pH8、pH9条件下HPCD对氯诺昔康的增溶量分别为0.499、1.791、2.405mg·ml-1。计算了不同pH下包合物的表观稳定常数,在pH7、pH8、pH9条件下表观稳定常数分别为132.42、66.53、38.60。结论难溶性药物氯诺昔康与2-羟丙基-β-环糊精可形成1∶1包合物,2-羟丙基-β-环糊精对于难溶性药物氯诺昔康是较理想的增溶剂。 Aim To study the solubilization effect of 2-hydroxypropyl-β-cyclodextrin, (HPCD) of various pH and concentrations on lomoxicam. Methods The solubization experiment was done by the phase-solubility method, and the concentration of lomoxicam was determined by the UV method. The stability constants(K) of the conclusion complex could be calculated from the regression equation: K = slope/intercept( 1-slope). Results The solubility of lomoxicam was enhanced rapidly with the increase of HPCD concentration and increase of pH. The solubilization effect on lomoxicam is 0.499, 1.791,2.405mg·ml^-1 at pH7, pH8, pH9. The stability constants were calculated at various pH. The stability constants(K) were 132.42,66.53,38.60 at pH7, pH8, pH9. Conclusion Lomoxicam-HP-CD conclusion complex could be formed,HPCD is a desirable solubilizer for lomoxicam.
出处 《解放军药学学报》 CAS 2006年第2期146-148,共3页 Pharmaceutical Journal of Chinese People's Liberation Army
关键词 氯诺昔康 2-羟丙基-Β-环糊精 溶解度 Lomoxicam HPCD Solubility
  • 相关文献

参考文献5

二级参考文献21

  • 1丁平田,吴雪梅.药物制剂的新型辅料2-羟丙基-β-环糊精[J].国外医药(合成药.生化药.制剂分册),1996,17(2):107-111. 被引量:62
  • 2[1]Pruss T P,Stroissing H,Radhofer W S,et al.Overview of the pharmacological properties,pharmacokinetics and animal safety assessment of lornoxicam[J].Postgrad.Med.J,1990,66:Suppl.4,18
  • 3[2]Urano H,Itoga H,Fukushima K,et al.Disposition of lornoxicam (2)-tissue distribution, foeto-placental transfer and tranfer into milk after single administration to rats[J].Kiso To Rinsho,1997,31(4):21
  • 4[3]Hitzenberger G,Radhofer Welte S,Takacs F,et al.Pharmacokinetics of lornoxicam in man[J].Postgrad.Med.J,1990,66:Suppl.4,22
  • 5[4]Turner P,Johnston-A.Clinical pharmacokinetic studies with lornoxicam[J].Postgrad.Med.J,1990,66:Suppl.4,28
  • 6[5]Atzpodien E,Mehdi N,Clarke D,et al.Subacute and chronic oral toxicity of lornoxicam in cynomolgus monkeys[J].Food-Chem-Toxocol,1997,35:ISS 5,465
  • 7[6]Pohlmeyer E G,Mehdi N,Clarke D,et al.Evaluation of chronic oral toxicity and carcinogenic potential of lornoxicam in rat[J].Food-Chem-Toxocol,1997,35:ISS 9,909
  • 8[7]Rosenow DE,van Krieken F,Stolke D,et al.Intravenous administration of lornoxicam,a new NSAID,and pethidine for postoperation pain[J].Clin Drug Invest,1996,11(1):11
  • 9[8]Balfour JA,Fitton A,Barradell LB.Lornixicam:A review of its pharmacology and therapeutic potential in the management of painful and inflammatory conditions[J].Drugs,1996,51(Apr):639
  • 10[9]Radhofer W S,Rabasseda.Lornoxicam,a new potent NSAID with an improved tolerability profile[J].Drugs of Today,2000,36(1):55

共引文献162

同被引文献75

引证文献9

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部